Sandu Pharmaceuticals share news and announcements
BSE: 524703Pharmaceuticals & BiotechnologySmall Cap
Last close ₹33.99up ₹0.99 (3.00%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹33.00.
52-week range of traded prices to 23 Oct 2026
₹30.00Low, 30 Mar 2026₹50.00High, 27 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹33 Cr3,677th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 18.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 5 May 2026
- 0.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.94%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 4.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 5.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 5 May 2026
- 0.01
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,719
Sandu Pharmaceuticals routine notices
297 filed, newest first. Page 6 of 6.
Aug 2019
Jul 2019
Jun 2019
May 2019
Apr 2019
Mar 2019
Feb 2019
Jan 2019
Dec 2018
Sep 2018
Jul 2018
Jan 2017
Oct 2016
Sep 2016
Jul 2016
May 2016
14 May · Routine
Meeting of the Board of Directors of the Company will be held on May 30, 2016, to consider and approve the Audited Financial Results for ....
Feb 2016
1 Feb · Routine
Ensuing Board Meeting of the Company will be held on February 13, 2016, inter alia , to consider and take on record the Un audited Financial ....
Oct 2015
31 Oct · Routine
Ensuing Board Meeting of the Company will be held on November 14, 2015, inter alia, to consider and take on record the Un-Audited Financial ....
Sep 2015
Aug 2015
28 Aug · Routine
With reference to the letter dated July 16, 2015 regarding Closure of Trading Window of the Company for the board meeting held on August 13, 2015, Sandu Pharmaceuticals Ltd has informed ....
Jul 2015
16 Jul · Routine
Ensuing Board Meeting of the Company will be held on August 13, 2015, inter alia, to consider and take on record the Un-Audited Financial ....
Apr 2015
10 Apr · Routine
Ensuing Board Meeting of the Company will be held on May 30, 2015, inter alia, to consider and take on record the Audited Financial Results ....